Mental Health After Dexmedetomidine for Electrical Storm
Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm: Outpatient Follow-up of Mental Health INDices (SDATE OF MIND)
Ottawa Heart Institute Research Corporation
70 participants
Mar 15, 2025
OBSERVATIONAL
Conditions
Summary
The goal of the research study is to measure mental health and quality of life indices of individuals treated for electrical storm (ES). The consequences of being admitted to an intensive care unit (ICU) with electrical storm as well as the treatments patients would have received, are currently not well understood. Understanding the mental health burden of these treatments among survivors can provide insights into how to improve care. This is a study consisting of patients who participated in the SEDATE trial (dexmedetomidine vs usual standard of care to treat ES in the ICU). Patients who consent to participate in this study will be asked to complete a set of questionnaires 3-6 months after their ICU admission. The purpose of the questionnaires is to measure indices of mental health and health-related quality of life. Each questionnaire will take about 5-15 minutes to complete. If patients have a scheduled follow-up at the University of Ottawa Heart Institute, a member of the research team will meet with them during their clinic visit to complete the questionnaires. Otherwise, they can be completed over the telephone.
Eligibility
Inclusion Criteria2
- Patients admitted to an intensive care unit with a diagnosis of electrical storm within the preceding 6 months
- Previous participants in the SEDATE trial (NCT06281977)
Exclusion Criteria1
- \- None
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dexmedetomidine infusion during ICU admission for electrical storm
Placebo (standard of care, no dexmedetomidine), for treatment of electrical storm while admitted to ICU
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07368062